Patent · US Active

Heterotricyclic metalloprotease inhibitors

US7749996B2 · kind B2 · utility

0Cited by

0References

14Claims

0Family size

Assignee

Alantos Pharmaceuticals Holding, Inc. · US

Inventors

Christian Gege · Ehingen (Donau), DE
Carine Chevrier · Munich, DE
Matthias Schneider · Dossenheim, DE
Harald Bluhm · Dossenheim, DE
Matthias Hochgürtel · Schriesheim, DE
Hongbo Deng · Southborough, US
Brian Gallagher · Merrimac, US
Irving Sucholeiki · Watertown, US
Arthur G. Taveras · Rockaway, US

Key dates

Filing date	Nov 20, 2007
Grant date	Jul 6, 2010
Priority date	—
Expiry date	Dec 12, 2027

Classification

Technology area (CPC C)Chemistry; Metallurgy
CPC primaryC07D513/04
WIPO fieldOrganic fine chemistry
WIPO sectorChemistry

Abstract

The present invention relates generally to azatriocyclic containing pharmaceutical agents, and in particular, to azatricyclic metalloprotease inhibiting compounds. More particularly, the present invention provides a new class of azatricyclic MMP-3, MMP-8 and/or MMP-13 inhibiting compounds, that exhibit an increased potency and selectivity in relation to currently known MMP-13, MMP-8 and MMP-3 inhibitors.

Source: USPTO / EPO open patent data. Objective bibliographic and citation counts.